BAX NYSE
Credit Risk of going bust: higher than 64% of companies Debt: 42.5% of company value Bonds: $263.3M held by 339 funds, 111 bp over Treasuries → details ▾
If the stock fell to about $1.46 (down 94%), Baxter International Inc. would be worth roughly what it owes.
Total debt $9.67B against a stock market value of $13.07B.
Distance to default 3.89 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $5.15B (short-term plus half of long-term), stock volatility 44.0%; Altman Z 2.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Deerfield, IL 60015
US
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rogers Terence John | 0 | — | 2026-10-01 | |
| Heine Bernard | 0 | — | 2026-09-15 | |
| Hider Andrew P. | F-InKind | 54,276 | $25.70 | 2026-09-02 |
| Foster Julie | F-InKind | 2,098 | $25.70 | 2026-09-02 |
| Wilkes David S. | A-Award | 12,836 | — | 2026-05-05 |